BioSpace News Archive

Abbisko Therapeutics Co., Ltd. announced that it has presented new phase II clinical data of its highly selective FGFR4 inhibitor irpagratinib in combination with atezolizumab for the treatment of advanced hepatocellular carcinoma（HCC）at the 2024 ESMO-GI Congress.

Dioseve Inc., aiming to develop assisted reproductive technology using oocytes derived from iPS cells, has raised 7 million USD.

Today, the U.S. Food and Drug Administration granted marketing authorization to Cepheid for the Xpert HCV test and GeneXpert Xpress System, the first hepatitis C virus (HCV) test that can be used to bring diagnosis to appropriately certified point-of-care settings for individuals at risk for hepatitis C.

Bioretec Ltd., a pioneer in bioresorbable orthopedic implants, announces that according to the information received from the Notified Body, its European CE mark market authorization application for the RemeOs™ trauma screw has returned from the expert panel evaluation.

Integer Holdings Corporation announced that it plans to release financial and operational results for second quarter 2024 at 7 a.m. Central Time / 8 a.m. Eastern Time on Thursday, July 25, 2024.

Accolade, Inc. (NASDAQ: ACCD) today announced financial results for the fiscal first quarter ended May 31, 2024.

Elicio Therapeutics, Inc. announced new preliminary data from the ongoing AMPLIFY-7P Phase 1a study of its off-the-shelf investigational therapeutic cancer vaccine candidate, ELI-002 7P.

Azitra, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, announced that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 30 pre-split shares.

Gain Therapeutics, Inc. announces that Matthias Alder has departed the Company in order to pursue other opportunities.

Dynavax Technologies Corporation (Nasdaq: DVAX) today announced that the first participant has been dosed in a Phase 1/2 clinical trial evaluating the safety, tolerability, and immunogenicity of Z-1018, the company’s investigational vaccine candidate being developed for the prevention of shingles (herpes zoster), a debilitating disease caused by the varicella-zoster virus.